^
FGFR2 rearrangement
|
Cholangiocarcinoma
|
FGFR2 rearrangement
|
Cholangiocarcinoma
|
pemigatinib Sensitive: A1 - Approval
JCO Precis Oncol - 5 days (NewA1)
|
pemigatinib Sensitive: A1 - Approval
JCO Precis Oncol - 5 days - (New C3)
|
FGFR2 fusion
|
Cholangiocarcinoma
|
FGFR2 fusion
|
Cholangiocarcinoma
|
pemigatinib Sensitive: A1 - Approval
JCO Precis Oncol - 5 days (NewA1)
|
pemigatinib Sensitive: A1 - Approval
JCO Precis Oncol - 5 days - (New C3)
|
No biomarker
|
Biliary Tract Cancer
|
No biomarker
|
Biliary Tract Cancer
|
durvalumab Sensitive: A2 - Guideline
AstraZeneca Press Release - 1 week (NewA2)
|
durvalumab Sensitive: A2 - Guideline
AstraZeneca Press Release - 1 week - (New B)
|
MSI-H/dMMR
|
Biliary Tract Cancer
|
MSI-H/dMMR
|
Biliary Tract Cancer
|
pembrolizumab Sensitive: A1 - Approval
Merck (MSD) Press Release - 2 weeks (NewA1)
|
pembrolizumab Sensitive: A1 - Approval
Merck (MSD) Press Release - 2 weeks - (New A1)
|
KRAS mutation
|
Biliary Tract Cancer
|
KRAS mutation
|
Biliary Tract Cancer
|
anlotinib + APL-502 Resistant: C3 – Early Trials
Hepatology - 2 weeks (NewC3)
|
anlotinib + APL-502 Resistant: C3 – Early Trials
Hepatology - 2 weeks - (New C3)
|
TMB-H
|
Biliary Tract Cancer
|
TMB-H
|
Biliary Tract Cancer
|
anlotinib + APL-502 Sensitive: C3 – Early Trials
Hepatology - 2 weeks (NewC3)
|
anlotinib + APL-502 Sensitive: C3 – Early Trials
Hepatology - 2 weeks - (New C3)
|
FDFT1 rearrangement + FGFR2 rearrangement
|
Cholangiocarcinoma
|
FDFT1 rearrangement + FGFR2 rearrangement
|
Cholangiocarcinoma
|
anlotinib Sensitive: C4 – Case Studies
Cancer Treat Res Commun - 3 weeks (NewC4)
|
anlotinib Sensitive: C4 – Case Studies
Cancer Treat Res Commun - 3 weeks - (New C4)
|
FGFR2 rearrangement
|
Cholangiocarcinoma
|
FGFR2 rearrangement
|
Cholangiocarcinoma
|
infigratinib Sensitive: A1 - Approval
|
infigratinib Sensitive: A1 - Approval
|
FGFR2 fusion
|
Cholangiocarcinoma
|
FGFR2 fusion
|
Cholangiocarcinoma
|
infigratinib Sensitive: A1 - Approval
|
infigratinib Sensitive: A1 - Approval
|
IDH1 mutation
|
Cholangiocarcinoma
|
IDH1 mutation
|
Cholangiocarcinoma
|
ivosidenib Sensitive: A1 - Approval
|
ivosidenib Sensitive: A1 - Approval
|
No biomarker
|
Gallbladder Cancer
|
No biomarker
|
Gallbladder Cancer
|
GC Sensitive: A2 - Guideline
|
GC Sensitive: A2 - Guideline
|
No biomarker
|
Gallbladder Cancer
|
No biomarker
|
Gallbladder Cancer
|
GemOx Sensitive: A2 - Guideline
|
GemOx Sensitive: A2 - Guideline
|
No biomarker
|
Gallbladder Cancer
|
No biomarker
|
Gallbladder Cancer
|
gemcitabine Sensitive: A2 - Guideline
|
gemcitabine Sensitive: A2 - Guideline
|
No biomarker
|
Biliary Tract Cancer
|
No biomarker
|
Biliary Tract Cancer
|
CAPOX Sensitive: A2 - Guideline
|
CAPOX Sensitive: A2 - Guideline
|
No biomarker
|
Gallbladder Cancer
|
No biomarker
|
Gallbladder Cancer
|
GEM-CAP Sensitive: A2 - Guideline
|
GEM-CAP Sensitive: A2 - Guideline
|
No biomarker
|
Biliary Tract Cancer
|
No biomarker
|
Biliary Tract Cancer
|
FP Sensitive: A2 - Guideline
|
FP Sensitive: A2 - Guideline
|
No biomarker
|
Gallbladder Cancer
|
No biomarker
|
Gallbladder Cancer
|
CAPOX Sensitive: A2 - Guideline
|
CAPOX Sensitive: A2 - Guideline
|
No biomarker
|
Gallbladder Cancer
|
No biomarker
|
Gallbladder Cancer
|
XP Sensitive: A2 - Guideline
|
XP Sensitive: A2 - Guideline
|
No biomarker
|
Gallbladder Cancer
|
No biomarker
|
Gallbladder Cancer
|
FP Sensitive: A2 - Guideline
|
FP Sensitive: A2 - Guideline
|
No biomarker
|
Biliary Tract Cancer
|
No biomarker
|
Biliary Tract Cancer
|
XP Sensitive: A2 - Guideline
|
XP Sensitive: A2 - Guideline
|
No biomarker
|
Cholangiocarcinoma
|
No biomarker
|
Cholangiocarcinoma
|
gemcitabine + albumin-bound paclitaxel Sensitive: A2 - Guideline
|
gemcitabine + albumin-bound paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Gallbladder Cancer
|
No biomarker
|
Gallbladder Cancer
|
capecitabine Sensitive: A2 - Guideline
|
capecitabine Sensitive: A2 - Guideline
|
No biomarker
|
Gallbladder Cancer
|
No biomarker
|
Gallbladder Cancer
|
5-fluorouracil Sensitive: A2 - Guideline
|
5-fluorouracil Sensitive: A2 - Guideline
|
No biomarker
|
Gallbladder Cancer
|
No biomarker
|
Gallbladder Cancer
|
cisplatin + gemcitabine + albumin-bound paclitaxel Sensitive: A2 - Guideline
|
cisplatin + gemcitabine + albumin-bound paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Gallbladder Cancer
|
No biomarker
|
Gallbladder Cancer
|
5-fluorouracil + oxaliplatin Sensitive: A2 - Guideline
|
5-fluorouracil + oxaliplatin Sensitive: A2 - Guideline
|
No biomarker
|
Cholangiocarcinoma
|
No biomarker
|
Cholangiocarcinoma
|
gemcitabine Sensitive: A2 - Guideline
|
gemcitabine Sensitive: A2 - Guideline
|
No biomarker
|
Biliary Tract Cancer
|
No biomarker
|
Biliary Tract Cancer
|
gemcitabine Sensitive: A2 - Guideline
|
gemcitabine Sensitive: A2 - Guideline
|
No biomarker
|
Biliary Tract Cancer
|
No biomarker
|
Biliary Tract Cancer
|
capecitabine Sensitive: A2 - Guideline
|
capecitabine Sensitive: A2 - Guideline
|
No biomarker
|
Biliary Tract Cancer
|
No biomarker
|
Biliary Tract Cancer
|
5-fluorouracil Sensitive: A2 - Guideline
|
5-fluorouracil Sensitive: A2 - Guideline
|
No biomarker
|
Biliary Tract Cancer
|
No biomarker
|
Biliary Tract Cancer
|
cisplatin + gemcitabine + albumin-bound paclitaxel Sensitive: A2 - Guideline
|
cisplatin + gemcitabine + albumin-bound paclitaxel Sensitive: A2 - Guideline
|
BRAF V600E
|
Biliary Tract Cancer
|
BRAF V600E
|
Biliary Tract Cancer
|
trametinib + dabrafenib Sensitive: A2 - Guideline
|
trametinib + dabrafenib Sensitive: A2 - Guideline
|
NTRK3 fusion
|
Biliary Tract Cancer
|
NTRK3 fusion
|
Biliary Tract Cancer
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Biliary Tract Cancer
|
NTRK2 fusion
|
Biliary Tract Cancer
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK3 fusion
|
Biliary Tract Cancer
|
NTRK3 fusion
|
Biliary Tract Cancer
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Biliary Tract Cancer
|
NTRK2 fusion
|
Biliary Tract Cancer
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK1 fusion
|
Biliary Tract Cancer
|
NTRK1 fusion
|
Biliary Tract Cancer
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK1 fusion
|
Biliary Tract Cancer
|
NTRK1 fusion
|
Biliary Tract Cancer
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
No biomarker
|
Biliary Tract Cancer
|
No biomarker
|
Biliary Tract Cancer
|
gemcitabine + oxaliplatin Sensitive: A2 - Guideline
|
gemcitabine + oxaliplatin Sensitive: A2 - Guideline
|
No biomarker
|
Biliary Tract Cancer
|
No biomarker
|
Biliary Tract Cancer
|
gemcitabine + capecitabine Sensitive: A2 - Guideline
|
gemcitabine + capecitabine Sensitive: A2 - Guideline
|
No biomarker
|
Biliary Tract Cancer
|
No biomarker
|
Biliary Tract Cancer
|
5-fluorouracil + oxaliplatin Sensitive: A2 - Guideline
|
5-fluorouracil + oxaliplatin Sensitive: A2 - Guideline
|
No biomarker
|
Biliary Tract Cancer
|
No biomarker
|
Biliary Tract Cancer
|
cisplatin + gemcitabine Sensitive: A2 - Guideline
|
cisplatin + gemcitabine Sensitive: A2 - Guideline
|
BRAF V600E
|
Biliary Tract Cancer
|
BRAF V600E
|
Biliary Tract Cancer
|
pembrolizumab + lenvatinib Sensitive: A2 - Guideline
|
pembrolizumab + lenvatinib Sensitive: A2 - Guideline
|
No biomarker
|
Biliary Tract Cancer
|
No biomarker
|
Biliary Tract Cancer
|
FOLFOX Sensitive: A2 - Guideline
|
FOLFOX Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Biliary Tract Cancer
|
MSI-H/dMMR
|
Biliary Tract Cancer
|
dostarlimab Sensitive: A2 - Guideline
|
dostarlimab Sensitive: A2 - Guideline
|
RET fusion
|
Biliary Tract Cancer
|
RET fusion
|
Biliary Tract Cancer
|
pralsetinib Sensitive: A2 - Guideline
|
pralsetinib Sensitive: A2 - Guideline
|
No biomarker
|
Biliary Tract Cancer
|
No biomarker
|
Biliary Tract Cancer
|
5-fluorouracil + irinotecan + leucovorin calcium Sensitive: A2 - Guideline
|
5-fluorouracil + irinotecan + leucovorin calcium Sensitive: A2 - Guideline
|
No biomarker
|
Cholangiocarcinoma
|
No biomarker
|
Cholangiocarcinoma
|
infigratinib Sensitive: B - Late Trials
|
infigratinib Sensitive: B - Late Trials
|
HER-2 expression
|
Biliary Tract Cancer
|
HER-2 expression
|
Biliary Tract Cancer
|
ZW25 Sensitive: B - Late Trials
|
ZW25 Sensitive: B - Late Trials
|
FGFR2 rearrangement
|
Cholangiocarcinoma
|
FGFR2 rearrangement
|
Cholangiocarcinoma
|
TAS 120 Sensitive: B - Late Trials
|
TAS 120 Sensitive: B - Late Trials
|
FGFR2 fusion
|
Cholangiocarcinoma
|
FGFR2 fusion
|
Cholangiocarcinoma
|
TAS 120 Sensitive: B - Late Trials
|
TAS 120 Sensitive: B - Late Trials
|
HER-2 expression
|
Cholangiocarcinoma
|
HER-2 expression
|
Cholangiocarcinoma
|
trastuzumab + lapatinib Sensitive: B - Late Trials
|
trastuzumab + lapatinib Sensitive: B - Late Trials
|
No biomarker
|
Biliary Tract Cancer
|
No biomarker
|
Biliary Tract Cancer
|
fosgemcitabine palabenamide Sensitive: B - Late Trials
|
fosgemcitabine palabenamide Sensitive: B - Late Trials
|
No biomarker
|
Cholangiocarcinoma
|
No biomarker
|
Cholangiocarcinoma
|
TT-00420 Sensitive: B - Late Trials
|
TT-00420 Sensitive: B - Late Trials
|
RET fusion
|
Cholangiocarcinoma
|
RET fusion
|
Cholangiocarcinoma
|
pralsetinib Sensitive: C1 - Off-label
|
pralsetinib Sensitive: C1 - Off-label
|
MSI-H/dMMR
|
Gallbladder Cancer
|
MSI-H/dMMR
|
Gallbladder Cancer
|
dostarlimab Resistant: C1 - Off-label
|
dostarlimab Resistant: C1 - Off-label
|
BRCA2 mutation
|
Cholangiocarcinoma
|
BRCA2 mutation
|
Cholangiocarcinoma
|
olaparib Sensitive: C1 - Off-label
|
olaparib Sensitive: C1 - Off-label
|
BRCA1 mutation
|
Cholangiocarcinoma
|
BRCA1 mutation
|
Cholangiocarcinoma
|
olaparib Sensitive: C1 - Off-label
|
olaparib Sensitive: C1 - Off-label
|
HER-2 overexpression
|
Gallbladder Cancer
|
HER-2 overexpression
|
Gallbladder Cancer
|
trastuzumab Sensitive: C1 - Off-label
|
trastuzumab Sensitive: C1 - Off-label
|
FGFR3 mutation
|
Cholangiocarcinoma
|
FGFR3 mutation
|
Cholangiocarcinoma
|
erdafitinib Sensitive: C1 - Off-label
|
erdafitinib Sensitive: C1 - Off-label
|
FGFR2 mutation
|
Cholangiocarcinoma
|
FGFR2 mutation
|
Cholangiocarcinoma
|
erdafitinib Sensitive: C1 - Off-label
|
erdafitinib Sensitive: C1 - Off-label
|
MSI-H/dMMR
|
Gallbladder Cancer
|
MSI-H/dMMR
|
Gallbladder Cancer
|
pembrolizumab Sensitive: C1 - Off-label
|
pembrolizumab Sensitive: C1 - Off-label
|
NTRK3 fusion
|
Cholangiocarcinoma
|
NTRK3 fusion
|
Cholangiocarcinoma
|
larotrectinib Sensitive: C1 - Off-label
|
larotrectinib Sensitive: C1 - Off-label
|
NTRK2 fusion
|
Cholangiocarcinoma
|
NTRK2 fusion
|
Cholangiocarcinoma
|
larotrectinib Sensitive: C1 - Off-label
|
larotrectinib Sensitive: C1 - Off-label
|
NTRK1 fusion
|
Cholangiocarcinoma
|
NTRK1 fusion
|
Cholangiocarcinoma
|
larotrectinib Sensitive: C1 - Off-label
|
larotrectinib Sensitive: C1 - Off-label
|
PD-L1 expression
|
Biliary Tract Cancer
|
PD-L1 expression
|
Biliary Tract Cancer
|
pembrolizumab Sensitive: C1 - Off-label
|
pembrolizumab Sensitive: C1 - Off-label
|
BRAF V600
|
Cholangiocarcinoma
|
BRAF V600
|
Cholangiocarcinoma
|
vemurafenib Sensitive: C1 - Off-label
|
vemurafenib Sensitive: C1 - Off-label
|
MSI-H/dMMR
|
Cholangiocarcinoma
|
MSI-H/dMMR
|
Cholangiocarcinoma
|
pembrolizumab Sensitive: C1 - Off-label
|
pembrolizumab Sensitive: C1 - Off-label
|
PD-L1 expression
|
Biliary Tract Cancer
|
PD-L1 expression
|
Biliary Tract Cancer
|
nivolumab + ipilimumab Sensitive: C1 - Off-label
|
nivolumab + ipilimumab Sensitive: C1 - Off-label
|
BRAF V600E
|
Cholangiocarcinoma
|
BRAF V600E
|
Cholangiocarcinoma
|
trametinib + dabrafenib Sensitive: C1 - Off-label
|
trametinib + dabrafenib Sensitive: C1 - Off-label
|
NTRK2 fusion
|
Cholangiocarcinoma
|
NTRK2 fusion
|
Cholangiocarcinoma
|
entrectinib Sensitive: C1 - Off-label
|
entrectinib Sensitive: C1 - Off-label
|
NTRK3 fusion
|
Cholangiocarcinoma
|
NTRK3 fusion
|
Cholangiocarcinoma
|
entrectinib Sensitive: C1 - Off-label
|
entrectinib Sensitive: C1 - Off-label
|
NTRK1 fusion
|
Cholangiocarcinoma
|
NTRK1 fusion
|
Cholangiocarcinoma
|
entrectinib Sensitive: C1 - Off-label
|
entrectinib Sensitive: C1 - Off-label
|
HER-2 positive
|
Biliary Tract Cancer
|
HER-2 positive
|
Biliary Tract Cancer
|
Herzuma (trastuzumab biosimilar) Sensitive: C1 - Off-label
|
Herzuma (trastuzumab biosimilar) Sensitive: C1 - Off-label
|
BRAF V600E
|
Biliary Tract Cancer
|
BRAF V600E
|
Biliary Tract Cancer
|
trametinib Sensitive: C1 - Off-label
|
trametinib Sensitive: C1 - Off-label
|
BRCA2 mutation
|
Biliary Tract Cancer
|
BRCA2 mutation
|
Biliary Tract Cancer
|
olaparib Sensitive: C1 - Off-label
|
olaparib Sensitive: C1 - Off-label
|
ATM mutation
|
Biliary Tract Cancer
|
ATM mutation
|
Biliary Tract Cancer
|
olaparib Sensitive: C1 - Off-label
|
olaparib Sensitive: C1 - Off-label
|
HER-2 positive
|
Biliary Tract Cancer
|
HER-2 positive
|
Biliary Tract Cancer
|
trastuzumab + pertuzumab Sensitive: C1 - Off-label
|
trastuzumab + pertuzumab Sensitive: C1 - Off-label
|
BRCA1 mutation
|
Gallbladder Cancer
|
BRCA1 mutation
|
Gallbladder Cancer
|
olaparib Sensitive: C1 - Off-label
|
olaparib Sensitive: C1 - Off-label
|
HER-2 overexpression
|
Cholangiocarcinoma
|
HER-2 overexpression
|
Cholangiocarcinoma
|
lapatinib Sensitive: C1 - Off-label
|
lapatinib Sensitive: C1 - Off-label
|
FGFR2 translocation
|
Cholangiocarcinoma
|
FGFR2 translocation
|
Cholangiocarcinoma
|
pemigatinib Sensitive: C2 – Inclusion Criteria
|
pemigatinib Sensitive: C2 – Inclusion Criteria
|
FGFR2 fusion
|
Cholangiocarcinoma
|
FGFR2 fusion
|
Cholangiocarcinoma
|
ARQ 087 Sensitive: C2 – Inclusion Criteria
|
ARQ 087 Sensitive: C2 – Inclusion Criteria
|
FGFR2 mutation
|
Cholangiocarcinoma
|
FGFR2 mutation
|
Cholangiocarcinoma
|
infigratinib Sensitive: C2 – Inclusion Criteria
|
infigratinib Sensitive: C2 – Inclusion Criteria
|
FGFR2 mutation
|
Cholangiocarcinoma
|
FGFR2 mutation
|
Cholangiocarcinoma
|
ARQ 087 Sensitive: C2 – Inclusion Criteria
|
ARQ 087 Sensitive: C2 – Inclusion Criteria
|
FGFR2 amplification
|
Cholangiocarcinoma
|
FGFR2 amplification
|
Cholangiocarcinoma
|
ARQ 087 Sensitive: C2 – Inclusion Criteria
|
ARQ 087 Sensitive: C2 – Inclusion Criteria
|
FGFR2 mutation
|
Cholangiocarcinoma
|
FGFR2 mutation
|
Cholangiocarcinoma
|
TAS 120 Sensitive: C2 – Inclusion Criteria
|
TAS 120 Sensitive: C2 – Inclusion Criteria
|
IDH2 mutation
|
Cholangiocarcinoma
|
IDH2 mutation
|
Cholangiocarcinoma
|
dasatinib Sensitive: C2 – Inclusion Criteria
|
dasatinib Sensitive: C2 – Inclusion Criteria
|
IDH1 R132C
|
Cholangiocarcinoma
|
IDH1 R132C
|
Cholangiocarcinoma
|
ivosidenib Sensitive: C2 – Inclusion Criteria
|
ivosidenib Sensitive: C2 – Inclusion Criteria
|
PD-L1 expression
|
Biliary Tract Cancer
|
PD-L1 expression
|
Biliary Tract Cancer
|
M7824 Sensitive: C2 – Inclusion Criteria
|
M7824 Sensitive: C2 – Inclusion Criteria
|
FGFR2 mutation
|
Cholangiocarcinoma
|
FGFR2 mutation
|
Cholangiocarcinoma
|
TT-00420 Sensitive: C2 – Inclusion Criteria
|
TT-00420 Sensitive: C2 – Inclusion Criteria
|
KRAS wild-type
|
Biliary Tract Cancer
|
KRAS wild-type
|
Biliary Tract Cancer
|
panitumumab Sensitive: C2 – Inclusion Criteria
|
panitumumab Sensitive: C2 – Inclusion Criteria
|
HER-2 overexpression
|
Biliary Tract Cancer
|
HER-2 overexpression
|
Biliary Tract Cancer
|
ZW25 Sensitive: C3 – Early Trials
|
ZW25 Sensitive: C3 – Early Trials
|
HER-2 mutation
|
Biliary Tract Cancer
|
HER-2 mutation
|
Biliary Tract Cancer
|
neratinib Sensitive: C3 – Early Trials
|
neratinib Sensitive: C3 – Early Trials
|
MET amplification
|
Gallbladder Cancer
|
MET amplification
|
Gallbladder Cancer
|
crizotinib Sensitive: C3 – Early Trials
|
crizotinib Sensitive: C3 – Early Trials
|
ERBB3 mutation
|
Gallbladder Cancer
|
ERBB3 mutation
|
Gallbladder Cancer
|
lapatinib Sensitive: C3 – Early Trials
|
lapatinib Sensitive: C3 – Early Trials
|
HER-2 amplification
|
Gallbladder Cancer
|
HER-2 amplification
|
Gallbladder Cancer
|
trastuzumab Sensitive: C3 – Early Trials
|
trastuzumab Sensitive: C3 – Early Trials
|
HER-2 amplification
|
Gallbladder Cancer
|
HER-2 amplification
|
Gallbladder Cancer
|
lapatinib Sensitive: C3 – Early Trials
|
lapatinib Sensitive: C3 – Early Trials
|
HER-2 amplification
|
Gallbladder Cancer
|
HER-2 amplification
|
Gallbladder Cancer
|
trastuzumab + lapatinib Sensitive: C3 – Early Trials
|
trastuzumab + lapatinib Sensitive: C3 – Early Trials
|
ATM mutation
|
Biliary Tract Cancer
|
ATM mutation
|
Biliary Tract Cancer
|
toripalimab Resistant: C3 – Early Trials
|
toripalimab Resistant: C3 – Early Trials
|
HER-2 amplification
|
Cholangiocarcinoma
|
HER-2 amplification
|
Cholangiocarcinoma
|
trastuzumab Sensitive: C3 – Early Trials
|
trastuzumab Sensitive: C3 – Early Trials
|
